• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Komisję ESC ds. Wytycznych Postępowania nadzoruje i koordynuje przygotowywanie
nowych wytycznych i stanowisk przez grupy robocze i inne grupy ekspertów. Komitet jest …

Introduction: Atrial fibrillation (AF) is increasing in prevalence and is associated with
significant morbidity and mortality. The optimal diagnostic and treatment strategies for AF are …

Kardiomiopatie definiuje się jako strukturalne oraz funkcjonalne nieprawidłowości mięśnia
komór, które nie wynikają z niedokrwienia na skutek choroby wieńcowej czy …

Fabry disease (FD) is an X‐linked lysosomal storage disorder caused by pathogenic
variants in the α‐galactosidase A (GLA) gene that leads to reduced or undetectable α …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive evidence review was conducted, focusing on 2006 through October 2012 and …

Hypertrophic cardiomyopathy (HCM) is a common inherited heart disease with diverse
phenotypic and genetic expression, clinical presentation, and natural history. HCM has been …